Unaudited Financial Results for the quarter and half year ended on September 2025 is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mercury Laboratories Ltd (pharmaceuticals, single segment) submitted its Q2 FY26 and H1 FY26 unaudited results. Revenue from operations stood at ₹1,900.86 lakhs in Q2 FY26 vs ₹1,819.40 lakhs in Q2 FY25 (up about 4.5% YoY), while H1 FY26 revenue was ₹3,714.40 lakhs vs about ₹3,522.59 lakhs in H1 FY25 (up about 5.4%). Net profit after tax for Q2 FY26 jumped sharply to roughly ₹164.33 lakhs from about ₹50.04 lakhs in Q2 FY25, with H1 FY26 PAT at ₹261.09 lakhs, indicating a much larger bottom-line gain than the modest top-line growth. Operating cash flow for H1 FY26 was positive at ₹131.84 lakhs (vs ₹167.61 lakhs in H1 FY25), while total assets rose to ₹7,403.42 lakhs and other equity grew to ₹5,455.84 lakhs. Statutory auditor Naresh & Co. issued an unqualified limited review report with no qualifications.
Profit growth far outpaced revenue growth, pointing to strong margin expansion and improved profitability for shareholders. The stock may react positively, though investors should note the modest revenue growth and slightly lower operating cash flow compared to the prior-year half.